Donor-Specific Antibody Detection by Single-Antigen Bead Assay for Renal Transplantation: A 2-Year Experience from South India

Mamidi Neeraja; Sreedhar Kesireddy; Neerudi Raj Kumar; Madasu Praveen Kumar; Potlapally Pullaiah; Raju Chittampalli

doi:10.4103/ijn.IJN_462_20

Donor-Specific Antibody Detection by Single-Antigen Bead Assay for Renal Transplantation: A 2-Year Experience from South India

Indian J Nephrol. 2023 May-Jun;33(3):170-176. doi: 10.4103/ijn.IJN_462_20. Epub 2023 Mar 2.

Authors

Mamidi Neeraja¹, Sreedhar Kesireddy¹, Neerudi Raj Kumar¹, Madasu Praveen Kumar¹, Potlapally Pullaiah¹, Raju Chittampalli¹

Affiliation

¹ Department of Transplant Immunology, Apollo Hospitals, Jubilee Hills, Hyderabad, Telangana, India.

Abstract

Introduction: Recipient sensitization against donor human leukocyte antigens (HLA) plays a key role in transplant rejection, and this risk is best minimized by efficient pre transplant antibody detection. Determination of antibody specificity with the highest sensitivity and degree of resolution to the allelic antigen level is achieved by using single-antigen bead (SAB) assay.

Methods: This study evaluated the correlation of Luminex cross match (LXM) with SAB assay for detection of donor-specific antibodies (DSA). A total of 2075 renal transplant patients were screened for the presence of DSA by LXM, complement-dependent cytotoxicity (CDC) cross match, and 125 patients for SAB from January 2018 to December 2019.

Results: There was a male preponderance among recipients (P < 0.0001), and the most affected age group was 21-40 years. HLA typing was done in 550/2075 by DNA PCR-reverse sequence-specific oligonucleotide probes (SSOP) method. HLA DSA by LXM was detected in 16.3% of recipients (338/2075). Majority 180/338 (53.2%) of the patients were class II DSA positive, (P < 0.0001). Among the class II DSA positive patients, 20/180 (11.1%) samples gave false-positive results by LXM. SAB for class I and class II HLA IgG antibodies was done in 125/338 renal transplant recipients, which included 20 recipients with false-positive class II Luminex DSA, to check whether the DSA detected were really donor specific or not. The results showed that although 20/125 patients had some antibodies detected in their serum, they were not against the donor HLA antigens, as per the HLA typing reports of the donors. When compared to SAB assay, LXM showed more discrepant results, particularly to class II DSA.

Conclusion: In conclusion, LXM, if used in combination with SAB assay and HLA typing of donors if necessary for virtual cross match, will help in avoiding unnecessary exclusion of donors for renal transplant recipients and also for post transplant monitoring of recipients, especially in cadaveric donor transplants.

Keywords: Donor–Specific Antibodies; Single antigen bead assay; luminex Cross match; renal transplantation.